Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
BLBLSMthis companyBlossomHill Therapeutics, Inc.	$14.26	-7.69×	-3.53×	0×	-5.52×	-69.0%	0.0%	0.0%	0.0%	46.0%	-43.4%	-10.3%	-0.17×	1.8×	0×	8.97×	0.0%	—	—	2	C
ACTUActuate Therapeutics Inc	$0.33	-5.77×	16.24×	0×	-5.22×	57.8%	0.0%	0.0%	0.0%	-280.5%	-270.1%	-14.9%	0.05×	0.57×	-1,110.88×	2.39×	0.0%	2	-56.06	2	C
AGIOAgios Pharmaceuticals, Inc.	$30.10	-3.82×	1.32×	29.21×	-3.74×	-87.2%	78.7%	-873.9%	-764.0%	-34.6%	-38.2%	-23.9%	0.03×	0.12×	0×	11.46×	0.0%	3	11.59	2	C
ALLRAllarity Therapeutics, Inc.	$0.98	-1.38×	1.58×	48.53×	-0.2×	20.0%	100.0%	-3939.1%	-3509.7%	-114.3%	-112.3%	-95.5%	0.14×	1.2×	-68.14×	2.13×	0.0%	1	-6.62	1	C-
AVBPArriVent BioPharma, Inc.	$13.98	-4.66×	2.52×	0×	-4.38×	-92.2%	0.0%	0.0%	0.0%	-54.1%	-57.8%	-20.8%	0×	0.27×	0×	12.83×	0.0%	2	12.15	2	C+
FHTXFoghorn Therapeutics Inc.	$2.01	-4.58×	-3.13×	11×	-4.24×	-713.4%	89.2%	-265.6%	-240.3%	68.5%	-58.9%	-25.3%	-0.38×	0.56×	0×	2.73×	0.0%	3	-4.44	2	C
Peer median	—	-4.58×	1.58×	11×	-4.24×	-87.2%	78.7%	-265.6%	-240.3%	-54.1%	-58.9%	-23.9%	0.03×	0.56×	0×	2.73×	0.0%	2	-4.44	2	—